Department of Urology, The Second People's Hospital of Wuhu, Wuhu, Anhui Province, China.
Department of Pathology, The Second People's Hospital of Wuhu, Wuhu, Anhui Province, China.
J Healthc Eng. 2022 Mar 19;2022:4993405. doi: 10.1155/2022/4993405. eCollection 2022.
Prostate cancer is one of the most common types of cancer found to occur in males and is ranked as the second-highest cause of cancer-associated deaths among male patients. In this study, we have shown the influence of a new palladium-based anticancer agent in contrast to the six distinct prostate cancer lines and the primary cultures.
In this study, we have used six distinct prostate cell lines, that is, PNT2-C2, LNCaP, BPH-1, PC-3, PNT1A, and P4E6. The MTP and ATP assay were performed to evaluate the growth of the cell and the flow cytometry to investigate the status of the cell cycle. The antigrowth effect of the palladium complex was evaluated against different cell lines at three time zones 24 h, 48 h, and 72 h. [PdCl(terpy)] (capsule)-2HO is synthesized by direct encapsulation of equimolar amounts of capsule ions into [Pd (terpy) Cl] Cl-2HO.
A comparative analysis was done on 25 mM etoposide and 12 mM cisplatin, cytotoxic agents. The lowest IC50 value at 72 hours was 0.128 mM for BPH-1 cell lines with 0.139 mM, whereas PNT2-C2 cells were found to be most resistant with IC50 values of 0.829 mM. The antigrowth effect of palladium complex on cell lines was measured using the MTS assay at 24, 48, and 72 hours. BPH-1, PNT2-C2, and PNT1A either possess normal tissues or have benign prostatic hyperplasia tissues whereas P4E6, PC-3, and LNCaP cell lines possess malignant origin. The Pd complex exhibited significant cytotoxic action in stem cells when compared against etoposide. An antigrowth effect was reported for Pd complex at lower concentration, but it was more cytotoxic than etoposide with significant cytotoxicity (=0.001).
The palladium complex experienced a substantial antigrowth influence over most of the prostate tumor cell lines and the primary cultures, eventually, leading to the implementation of this Pd complex in the treating procedure of metastatic prostate cancer, which is tremendously resistant to the traditional treatment.
前列腺癌是男性中最常见的癌症类型之一，也是男性癌症相关死亡的第二大主要原因。在本研究中，我们展示了一种新型钯基抗癌药物对六种不同前列腺癌细胞系和原代培养物的影响。
在本研究中，我们使用了六种不同的前列腺癌细胞系，即 PNT2-C2、LNCaP、BPH-1、PC-3、PNT1A 和 P4E6。采用 MTP 和 ATP 测定法评估细胞生长情况，采用流式细胞术检测细胞周期状态。在 24、48 和 72 小时三个时间点评估钯络合物对不同细胞系的抗生长作用。[PdCl(terpy)]（胶囊）-2HO 通过等摩尔量胶囊离子直接包封合成[Pd（terpy）Cl]Cl-2HO。
对 25mM 依托泊苷和 12mM 顺铂两种细胞毒性药物进行了比较分析。BPH-1 细胞系的最低 IC50 值在 72 小时时为 0.128mM，而 PNT2-C2 细胞系的 IC50 值最高，为 0.829mM。使用 MTS 测定法在 24、48 和 72 小时测量钯络合物对细胞系的抗生长作用。BPH-1、PNT2-C2 和 PNT1A 要么具有正常组织，要么具有良性前列腺增生组织，而 P4E6、PC-3 和 LNCaP 细胞系则具有恶性起源。与依托泊苷相比，钯络合物在干细胞中表现出显著的细胞毒性作用。钯络合物在较低浓度下表现出抗生长作用，但它比依托泊苷更具细胞毒性，且具有显著的细胞毒性（=0.001）。
钯络合物对大多数前列腺肿瘤细胞系和原代培养物产生了显著的抗生长作用，最终将该 Pd 络合物应用于转移性前列腺癌的治疗过程中，该癌症对传统治疗方法具有极强的耐药性。
